萎缩孔综合征与肾功能正常的2型糖尿病患者全因死亡的关系:Fremantle糖尿病研究II期
在Fremantle糖尿病研究II期1481例2型糖尿病参与者中,1466例接受基线eGFRcreat和eGFRcyst评估并随访10年或直至死亡。eGFRcyst/eGFRcreat比值每增加0.1,死亡风险独立降低(校正HR 0.91,95%CI 0.85–0.97,p=0.004);比值<0.60与死亡风险独立升高相关(HR 1.56,95%CI 1.07–2.29,p=0.021),在肾功能正常亚组(n=754)中比值<0.60者死亡风险亦独立升高(HR 2.55,95%CI 1.34–4.84,p=0.004)。
要点
- 在2型糖尿病中,eGFRcyst/eGFRcreat比值每增加0.1,死亡风险独立降低(校正HR 0.91,95%CI 0.85–0.97,p=0.004)。
- eGFRcyst/eGFRcreat比值<0.60(萎缩孔综合征定义)与全因死亡风险独立升高相关(HR 1.56,95%CI 1.07–2.29,p=0.021)。
- 在肾功能正常亚组中,eGFRcyst/eGFRcreat比值<0.60者死亡风险亦独立升高(HR 2.55,95%CI 1.34–4.84,p=0.004)。
核心结论
- 低eGFRcyst/eGFRcreat比值与2型糖尿病患者死亡独立相关,包括无常规糖尿病肾脏病标志物者。
- 萎缩孔综合征的存在可能为2型糖尿病患者的风险评估增加临床价值,无论其肾脏状态如何。
研究设计与样本
- Fremantle糖尿病研究II期为纵向观察性研究,纳入1481例年龄≥17岁的2型糖尿病参与者,其中1466例在基线评估中检测了eGFRcreat和eGFRcyst并随访10年或直至死亡(以先发生者为准)。
- 采用Cox回归模型确定死亡的独立相关因素(排除eGFR),随后将eGFRcyst/eGFRcreat比值分别作为分类变量或连续变量加入该模型。
- 上述分析也在基线肾功能正常(eGFRcreat ≥60 ml/min per 1.73 m2且尿白蛋白/肌酐比值<3 mg/mmol)的亚组(n=754)中进行。
主要发现
- 入组时参与者平均年龄65.9岁,男性占51.8%,糖尿病病程中位数9.0年,10.4%的参与者eGFRcyst/eGFRcreat比值<0.60(萎缩孔综合征定义)。
- 随访期间共384例死亡(26.2%)。
- eGFRcyst/eGFRcreat比值与死亡独立、显著且负相关(比值每增加0.1的校正HR 0.91,95%CI 0.85–0.97,p=0.004)。
- 在eGFRcyst/eGFRcreat比值分类中,仅<0.60类别显著加入最简约的死亡时间Cox模型(HR 1.56,95%CI 1.07–2.29,p=0.021)。
- 在肾功能正常亚组中,随访期间123例(16.3%)死亡,57例(7.6%)观察到eGFRcyst/eGFRcreat比值<0.60,该比值<0.60亦与死亡独立相关(HR 2.55,95%CI 1.34–4.84,p=0.004)。
关键数值与推荐
- 萎缩孔综合征(SPS)定义为eGFRcyst/eGFRcreat比值<0.60。
- 肾功能正常定义为eGFRcreat ≥60 ml/min per 1.73 m2且尿白蛋白/肌酐比值<3 mg/mmol。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Estimated GFRs utilising creatinine- (eGFRcreat) or cystatin C-based (eGFRcyst) equations can generate discrepant results that are associated with clinical outcomes. A low eGFRcyst/eGFRcreat ratio (<0.60), reflecting a pathological glomerular state termed shrunken pore syndrome (SPS), has been associated with excess mortality in some clinical situations including diabetes. The aim of the present study was to explore this association in a longitudinal observational study of type 2 diabetes with special reference to participants with normal renal function. METHODS: Of 1481 Fremantle Diabetes Study Phase II participants with type 2 diabetes, aged ≥17 years, 1466 had eGFRcreat and eGFRcyst assessed as part of the baseline assessment and were followed for 10 years or until death, whichever came first. Cox regression modelling was used to determine independent associates of death excluding eGFR; eGFRcyst/eGFRcreat ratio was then added to this model separately as a categorical or continuous variable. These analyses were also conducted in a subgroup (n=754) of participants with normal renal function (eGFRcreat ≥60 ml/min per 1.73 m2 and urinary albumin/creatinine ratio <3 mg/mmol) at baseline. RESULTS: At entry, the participants had a mean age of 65.9 years, 51.8% were male, the median diabetes duration was 9.0 years and 10.4% had eGFRcyst/eGFRcreat ratio <0.60 (the definition of SPS). There were 384 deaths (26.2%) during follow-up. The eGFRcyst/eGFRcreat ratio was independently, significantly and negatively associated with death (adjusted HR [95% CI] 0.91 [0.85, 0.97] for an increase of 0.1, p=0.004). Of eGFRcyst/eGFRcreat ratio categories, only <0.60 added significantly to the most parsimonious Cox model of time to death (HR [95% CI] 1.56 [1.07, 2.29], p=0.021). In those with normal renal function, 123 (16.3%) died during follow-up. An eGFRcyst/eGFRcreat ratio <0.60, observed in 57 (7.6%), was also independently associated with mortality (HR [95% CI] 2.55 [1.34, 4.84], p=0.004). CONCLUSIONS/INTERPRETATION: A low eGFRcyst/eGFRcreat ratio is independently associated with mortality in type 2 diabetes, including in people without conventional markers of diabetic kidney disease. The presence of SPS may add clinical value to the risk assessment of people with type 2 diabetes regardless of renal status.
引用
- Bruce DG, Davis WA, Chubb SAP, et al. The relationship between shrunken pore syndrome and all-cause mortality in people with type 2 diabetes and normal renal function: the Fremantle Diabetes Study Phase II. Diabetologia. 2025. PMID: 40257600. doi:10.1007/s00125-025-06430-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。